Introduction
============

Coronary atherosclerosis is a chronic inflammatory vascular disease and is initiated as a result of endothelial damage and dysfunction, which lead to the accumulation and oxidation of low density lipoprotein (LDL)-cholesterol in the arterial wall ([@b1-br-0-0-1152],[@b2-br-0-0-1152]) Monocytes migrate from the blood into the subendothelial intima and transform into macrophages, which then accumulate lipid particles (foam cells) to form the lipid core of atherosclerotic plaques ([@b2-br-0-0-1152],[@b3-br-0-0-1152]). Inflammatory and thrombotic processes serve central roles in the formation of atherosclerotic lesions and subsequent plaque rupture, which lead toward acute coronary syndrome ([@b2-br-0-0-1152],[@b3-br-0-0-1152]).

Coronary artery disease (CAD) and myocardial infarction (MI) are serious clinical conditions that remain the leading cause of mortality in the United States ([@b4-br-0-0-1152]). Disease prevention is an important strategy for reducing the overall burden of CAD and MI, with the identification of biomarkers for disease risk being key for risk prediction and for potential intervention, in order to reduce the chance of future adverse coronary events. In addition to conventional risk factors for CAD, including hypertension, diabetes mellitus and dyslipidemia, the importance of genetic factors has been highlighted ([@b5-br-0-0-1152]--[@b7-br-0-0-1152]). Genes responsible for familial hypercholesterolemia and Tangier disease are prototypical examples of monogenic forms of CAD and MI with Mendelian inheritance ([@b5-br-0-0-1152],[@b8-br-0-0-1152]). Familial hypercholesterolemia is an autosomal dominant disorder characterized by marked increases in the circulating concentrations of total cholesterol and LDL-cholesterol caused by mutations of the genes for LDL receptor (*LDLR*), apolipoprotein B (*APOB*), proprotein convertase subtilisin/kexin type 9 (*PCSK9*), cytochrome P450 family 7 subfamily A member 1 (*CYP7A1*) or LDL receptor adaptor protein 1 (*LDLRAP1*) ([@b9-br-0-0-1152],[@b10-br-0-0-1152]). Tangier disease is an autosomal recessive disorder characterized by a decrease in the circulating concentration of high density lipoprotein (HDL)-cholesterol as a result of loss-of-function mutations in the ATP-binding cassette subfamily A member 1 gene (*ABCA1*) ([@b11-br-0-0-1152]--[@b13-br-0-0-1152]). The etiology of common forms of CAD is multifactorial and includes genetic components, as well as environmental and lifestyle factors ([@b5-br-0-0-1152]--[@b8-br-0-0-1152]). The heritability of common forms of CAD has been estimated to be 40--60% on the basis of family and twin studies ([@b6-br-0-0-1152],[@b7-br-0-0-1152],[@b14-br-0-0-1152]).

Genome-wide association studies (GWASs) in European-ancestry ([@b15-br-0-0-1152]--[@b21-br-0-0-1152]), African American ([@b22-br-0-0-1152]) or Han Chinese populations ([@b23-br-0-0-1152],[@b24-br-0-0-1152]) have identified various genes and loci that confer susceptibility to CAD or MI. A meta-analysis of GWASs for CAD among European-ancestry populations, including low-frequency variants, identified 202 independent genetic variants at 129 loci with a false discovery rate (FDR) of \<5% ([@b25-br-0-0-1152]). These genetic variants together accounted for \~28% of the heritability of CAD, demonstrating that genetic susceptibility to this condition is largely determined by common variants with small effect sizes ([@b6-br-0-0-1152],[@b25-br-0-0-1152]). A more recent meta-analysis for CAD in European-ancestry populations identified 304 independent genetic variants with an FDR of \<5%, and these variants accounted for 21.2% of the heritability of CAD ([@b26-br-0-0-1152]). In total, GWASs identified 163 loci associated with CAD at a genome-wide significance level and \>300 possible loci for this condition with an FDR of \<5% ([@b7-br-0-0-1152]). Although several single nucleotide polymorphisms (SNPs) have been revealed to be significantly associated with MI in Japanese patients ([@b27-br-0-0-1152],[@b28-br-0-0-1152]), genetic variants that contribute toward susceptibility to CAD and MI in Japanese patients remain to be definitively identified.

A study of monozygotic and dizygotic twins revealed that mortality from CAD at younger ages was significantly influenced by genetic factors in males and females, whereas the genetic effect was smaller at older ages ([@b29-br-0-0-1152],[@b30-br-0-0-1152]). A family history of MI is also more apparent in individuals with early-onset MI than in those with late-onset MI, suggestive of a greater heritability in the former ([@b31-br-0-0-1152],[@b32-br-0-0-1152]).

The present study included exome-wide association studies (EWASs) for CAD with the use of human exome array-based genotyping methods in order to identify genetic variants that confer susceptibility to this condition in Japanese patients. In order to increase the statistical power of the EWAS, patients with early-onset CAD were examined.

Materials and methods
=====================

### Study subjects

In our previous EWAS, the median age of subjects with CAD was 69 years ([@b33-br-0-0-1152]). Therefore, patients with an age of ≤65 years were defined as individuals with early-onset CAD in the present study. A total of 7,256 Japanese subjects aged ≤65 years \[mean age, 51.7 years; age range, 18--65 years; males/females (%), 58.3/41.7; 1,482 with CAD, including 1,152 with MI, and 5,774 controls\] were enrolled in the present study. The subjects were individuals who either visited outpatient clinics or were admitted to participating hospitals in Japan (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya; Northern Mie Medical Center Inabe General Hospital, Inabe; and Hirosaki University Hospital and Hirosaki Stroke and Rehabilitation Center, Hirosaki, Japan) due to various symptoms or for an annual health check-up between October 2002 and March 2014, or who were community-dwelling individuals recruited to a population-based cohort study in Inabe between March 2010 and September 2014 ([@b34-br-0-0-1152]).

The diagnosis of CAD was based on the detection of stenosis of \>50% in any major coronary artery or in the left main trunk by coronary angiography. The diagnosis of MI was based on typical electrocardiographic changes and on increases in the serum activity of creatine kinase (MB isozyme) and in the serum concentration of troponin T. The diagnosis was confirmed by identification of the responsible stenosis in any of the major coronary arteries or in the left main trunk by coronary angiography. The control individuals had no history of MI, CAD, aortic aneurysm or peripheral artery disease; of ischemic or hemorrhagic stroke; or of other atherosclerotic, thrombotic, embolic or hemorrhagic disorders. Although certain control individuals had conventional risk factors for CAD, including hypertension, diabetes mellitus, dyslipidemia and CKD, they did not have any cardiovascular complications.

### EWAS

Venous blood (5 or 7 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated, and genomic DNA was extracted from these cells with the use of a DNA extraction kit (Genomix; Talent SRL, Trieste, Italy; or SMITEST EX-R&D; Medical & Biological Laboratories, Co., Ltd., Nagoya, Japan). The EWASs for CAD (1,482 cases and 5,774 controls) was performed with the use of a Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, Inc., San Diego, CA, USA). These exome arrays include putative functional exonic variants selected from \~12,000 individual exome and whole-genome sequences. The exonic content consists of \~244,000 SNPs from European, African, Chinese and Hispanic individuals ([@b35-br-0-0-1152]). SNPs contained in only one of the exome arrays (\~2.6% of all SNPs) were excluded from analysis. Quality control was performed as follows ([@b36-br-0-0-1152]): i) Genotyping data with a call rate of \<97% were discarded, with the mean call rate for the remaining data being 99.9%; ii) gender specification was checked for each sample, and those for which gender phenotype in the clinical records was inconsistent with genetic sex were discarded; iii) duplicate samples and cryptic relatedness were checked by calculation of identity by descent, and all pairs of DNA samples exhibiting an identity by descent of \>0.1875 were inspected and one sample from each pair was excluded; iv) the frequency of heterozygosity for SNPs was calculated for all samples, and those with extremely low or high heterozygosity (\>3 standard deviations from the mean) were discarded; v) SNPs in sex chromosomes or mitochondrial DNA were excluded from the analysis, as were nonpolymorphic SNPs or SNPs with a minor allele frequency of \<1.0%; vi) SNPs whose genotype distributions deviated significantly (P\<0.01) from Hardy-Weinberg equilibrium in control individuals were discarded; and vii) genotype data were examined for population stratification by principal components analysis ([@b37-br-0-0-1152]), and population outliers were excluded from the analysis. A total of 31,465 SNPs passed quality control for the EWASs of CAD and these SNPs were subjected to analyses.

### Statistical analysis

For analysis of the characteristics of the study subjects, quantitative data were compared between subjects with CAD and controls using the unpaired Student\'s t-test. Categorical data were compared between the two groups using the Pearson\'s χ^2^ test. Allele frequencies were estimated by the gene counting method, and Fisher\'s exact test was applied to identify departure from the Hardy-Weinberg equilibrium. In the EWAS, the association between allele frequencies of each SNP and CAD was examined using the Fisher\'s exact test. The genomic inflation factor (λ) was 0.93. To compensate for multiple comparisons of genotypes with CAD, an FDR was applied for statistical significance of association ([@b38-br-0-0-1152]). The significance level was set at an FDR of \<0.05 for the EWAS. Multivariable logistic regression analysis was performed with CAD as a dependent variable and independent variables, including age, sex (0, female and 1, male), the prevalence of hypertension, diabetes mellitus, and dyslipidemia (0, no history of these conditions; 1, positive history), as well as the genotype of each SNP. Genotypes of the SNPs were assessed according to dominant \[0, AA; 1, AB + BB (A, major allele; B, minor allele)\] and recessive (0, AA + AB; 1, BB) genetic models, and the P-value, odds ratio and 95% confidence interval were calculated. A stepwise forward selection procedure was also performed to examine the effects of genotypes on CAD. The P-levels for inclusion in and exclusion from the model were 0.25 and 0.1, respectively. In the stepwise forward selection procedure, each genotype was examined according to a dominant or recessive model on the basis of statistical significance in the multivariable logistic regression analysis. The association between genotypes of SNPs and intermediate phenotypes of CAD was examined using the Pearson\'s χ^2^ test. With the exception of the initial EWAS by the Fisher\'s exact test (FDR \<0.05), P\<0.05 was considered to indicate a statistically significant difference. Statistical tests were performed using JMP Genomics version 9.0 software (SAS Institute, Inc., Cary, NC, USA).

### Association between genes, chromosomal loci and SNPs identified in the present study and phenotypes previously reported by GWASs

The genes, chromosomal loci, and SNPs identified in the present study were compared with the cardiovascular disease-related phenotypes previously reported by GWASs available in the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search database v. 2.0.0.0 (<https://grasp.nhlbi.nih.gov/Search.aspx>), developed by the Information Technology and Applications Center at the National Center for Biotechnology Information (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA) ([@b39-br-0-0-1152],[@b40-br-0-0-1152]).

### Gene Ontology analysis

Biological functions of the genes were examined by the use of the Gene Ontology and GO Annotations databases (QuickGO version 2018; <https://www.ebi.ac.uk/QuickGO/>; European Bioinformatics Institute, European Molecular Biology Laboratory, Hinxton, Cambridgeshire, UK) ([@b41-br-0-0-1152],[@b42-br-0-0-1152]).

### Network analysis of gene-gene interactions

Network analyses were performed to predict functional gene-gene interactions by the use of GeneMANIA Cytoscape plugin (<http://apps.cytoscape.org/apps/genemania>; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada) ([@b43-br-0-0-1152]--[@b45-br-0-0-1152]) using Cytoscape v3.4.0 software (<http://www.cytoscape.org/>; The Cytoscape Consortium, San Diego, CA, USA) ([@b46-br-0-0-1152]). To begin with, the 30 genes (*ACE, NOS3, CCL2, PON1, CD40LG, LOX, APOB, CRP, APOA1, LPA, ESR1, LDLR, APOC3, VEGFA, LTA, HMOX1, MMP3, APOA5, PCSK9, CDKN2B, TLR4, GNB3, PTGS2, NPPB, ABCG8, ESR2, CXCL12, MIA3, IRS1* and *ABO*) were selected from the DisGeNET database (<http://www.disgenet.org/web/DisGeNET>; Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Barcelona Biomedical Research Park, Barcelona, Spain) ([@b47-br-0-0-1152],[@b48-br-0-0-1152]), according to the rank order of high scores in association with CAD. Next, the 234 genes previously identified by GWASs ([@b7-br-0-0-1152]) were selected, among which six genes were not included in GeneMANIA database and had no interaction with other genes. Therefore, the 228 genes (*SKI, PRDM16, FHL3, PCSK9, PPAP2B, SORT1, NGF, CASQ2, TDRKH, IL6R, ATP1B1, NME7, DDX59, CAMSAP2, LMOD1, HHAT, SERTAD4, DIEXF, MIA3, AGT, APOB, ABCG5, ABCG8, PRKCE, VAMP5, VAMP8, GGCX, ZEB2, FIGN, CALCRL, TFPI, WDR12, NBEAL1, FN1, TNS1, IRS1, KCNJ13, COL6A3, FGD5, ALS2CL, RTP3, CDC25A, SPINK8, MAP4, ZNF589, RHOA, ITGB5, DNAJC13, STAG1, MSL2, NCK1, PPP2R3A, MRAS, ARHGEF26, TIPARP, FNDC3B, RGS12, REST, NOA1, STBD1, PRDM8, FGF5, HNRNPD, UNC5C, MAD2L1, PDE5A, ZNF827, EDNRA, PALLD, SEMA5A, MAP3K1, LOX, SLC22A4, IL5, RAD50, ARHGAP26, FOXC1, PHACTR1, EDN1, HDGFL1, C2, ANKS1A, PI16, KCNK5, VEGFA, RAB23, FAM46A, CENPW, TCF21, PLEKHG1, LPA, PLG, MAD1L1, DAGLB, RAC1, KDELR2, TMEM106B, HDAC9, CCM2, BCAP29, GPR22, CFTR, ZC3HC1, KLHDC10, PARP12, TBXAS1, NOS3, NAT2, LPL, BMP1, ZFPM2, TRIB1, KLF4, SVEP1, DAB2IP, ABO, CDC123, KIAA1462, CXCL12, TSPAN14, FAM213A, LIPA, CYP17A1, CNNM2, NT5C2, SH3PXD2A, HTRA1, TRIM5, TRIM22, TRIM6, SWAP70, CTR9, ARNTL, HSD17B12, SIPA1, SERPINH1, ARHGAP42, PDGFD, APOA1, APOC3, APOA4, APOA5, C1S, PRPF31, HOXC4, LRP1, FGD6, SH2B3, KSR2, HNF1A, CCDC92, SCARB1, FLT1, N4BP2L2, PDS5B, COL4A1, COL4A2, MCF2L, CUL4A, ARID4A, PSMA3, TMED10, SERPINA1, HHIPL1, YY1, TRIP4, SMAD3, ADAMTS7, MFGE8, FURIN, FES, CETP, HP, CFDP1, BCAR1, PLCG2, CDH13, SMG6, PEMT, CORO6, BLMH, ANKRD13B, GIT1, SSH2, EFCAB5, COPRS, RAB11FIP4, DHX58, KAT2A, RAB5, NKIRAS2, DNAJC7, KCNH4, HCRT, GHDC, GOSR2, UBE2Z, GIP, BCAS3, PECAM1, DDX5, TEX2, ACAA2, RPL17, PMAIP1, MC4R, LDLR, SMARCA4, FCHO1, COLGALT1, ZNF507, HNRNPUL1, TGFB1, APOE, APOC1, PVRL2, COTL1, SNRPD2, PROCR, EIF6, ZHX3, PLCG1, PLTP, MMP9, ZNF831, BACH1, KCNE2* and *ADORA2A*) were applied to analysis.

Results
=======

### Characteristics of subjects

The characteristics of the 7,256 subjects enrolled in the present study are presented in [Table I](#tI-br-0-0-1152){ref-type="table"}. The age, the frequency of males, and the prevalence of obesity, hypertension, diabetes mellitus (DM), dyslipidemia, chronic kidney disease (CKD) and hyperuricemia, as well as body mass index, systolic and diastolic blood pressure, fasting plasma glucose level, blood glycosylated hemoglobin (hemoglobin A1c) content, and the serum concentrations of triglycerides, creatinine, and uric acid were greater, whereas the serum concentration of HDL-cholesterol and estimated glomerular filtration rate were lower, in patients with CAD than in controls.

### EWAS for CAD

The association between allele frequencies for 31,465 SNPs that passed quality control and CAD was examined using the Fisher\'s exact test, and the 170 SNPs were significantly (FDR \<0.05) associated with CAD ([Table II](#tII-br-0-0-1152){ref-type="table"}).

### Multivariable logistic regression analysis of the association between SNPs and CAD

The association between the 170 SNPs identified in the EWAS for CAD and this condition was examined by multivariable logistic regression analysis with adjustment for age, sex and the prevalence of hypertension, diabetes mellitus and dyslipidemia ([Table III](#tIII-br-0-0-1152){ref-type="table"}). The 162 SNPs were significantly (P\<0.05 in a dominant or recessive model) associated with CAD.

### Stepwise forward selection procedure of the effects of SNPs on CAD

A stepwise forward selection procedure was performed to examine effects of genotypes for the 162 SNPs associated with CAD by multivariable logistic regression analysis on this condition ([Table IV](#tIV-br-0-0-1152){ref-type="table"}). The 54 SNPs were significant (P\<0.05) and independent \[coefficient of determination (R^2^), 0.0008 to 0.0297\] determinants of CAD. These SNPs together accounted for 15.5% of the cause of CAD.

### Association between SNPs associated with CAD and intermediate phenotypes

The association between the 54 SNPs associated with CAD and intermediate phenotypes of this condition, including hypertension, DM, hypertriglyceridemia, hypo-HDL-cholesterolemia, hyper-low density lipoprotein (LDL)-cholesterolemia, CKD, obesity, and hyperuricemia, was examined using Pearson\'s χ^2^ test ([Table V](#tV-br-0-0-1152){ref-type="table"}).

The SNP rs671 of *ALDH2* was significantly (P\<0.05) associated with all the intermediate phenotypes; rs200787930 of *PLCB2* and rs2074356 of *HECTD4* to six of the eight phenotypes; rs9466 of *EIF3L* to five of the eight phenotypes; rs130071 of *CCHCR1*, rs11823828 of *OR52E4* and rs12229654 to four of the eight phenotypes; rs11174549 of *MON2*, rs10514995, rs507666, rs10757283 and rs78201384 of *CUBN* to three of the eight phenotypes; rs1046592 of *RNF2*, rs13427905, rs3094663 of *PSORS1C1*, rs6067640, rs592229 of *SKIV2L*, rs4014195, rs7333181, rs838880, rs1333048, rs10771894 of KIAA1551, rs954750 of *PLUT*, rs10794720 of *WDR37*, rs34052647 of *LIPE*, rs602633, rs145121731 of *MKI67*, rs41288947 of *USP45*, and rs9414827 of *PRKG1* to two of the eight phenotypes; and rs73053944 of *GFY*, rs6825911, rs1011970 of *CDKN2B-AS1*, rs1049434 of *SLC16A1*, rs145161932 of *ADAT1*, rs1052586 of *GOSR2*, rs197932, rs1883025 of *ABCA1*, rs76174573 of *YEATS2*, rs80015015 of *ITGB8*, rs2936051 of *MIA3*, rs7412 of *APOE*, rs4907518 of *LINC00354*, rs6537384, rs17558532 of *KRT27*, rs11185790 of *PANK1*, and rs2523644 to one of the eight phenotypes.

### Linkage disequilibrium analyses

Linkage disequilibrium (LD) was examined among SNPs associated with CAD. There was significant LD among rs12229654 at 12q24.1, rs671 of *ALDH2*, and rs2074356 of *HECTD4* \[square of the correlation coefficient (r^2^), 0.564 to 0.882)\].

### Association between genes, chromosomal loci and SNPs identified in the present study and phenotypes previously reported by GWASs

The association between genes, chromosomal loci and SNPs identified in the present study and cardiovascular disease-related phenotypes previously reported by GWASs available in the GRASP Search database ([Table VI](#tVI-br-0-0-1152){ref-type="table"}). Chromosomal region 1p13.3, *MIA3, PHACTR1, SKIV2L, CDKN2B-AS1, 9p21, ALDH2* and *HECTD4* were previously revealed to be associated with CAD or MI. *SLC16A1, PSORS1C1, CCHCR1, 6p21.3, ABCA1, 9q34.2, CUBN, PANK1, 12q24.1, 12q24.31, PLCB2* and *APOE* were previously associated with circulating concentrations of LDL-cholesterol, HDL-cholesterol, triglycerides or insulin, or type 1 diabetes mellitus. Chromosome 4q24, 17q21.3 and *GOSR2* were previously associated with systolic or diastolic blood pressure or pulse pressure. *CCDC141, TNS1, WDR37* and *11q13*.1 were previously associated with cardiac, pulmonary or renal function. The remaining 21 genes (*RNF2, YEATS2, USP45, ITGB8, TNS3, FAM170B-AS1, PRKG1, BTRC, MKI67, STIM1, OR52E4, KIAA1551, MON2, PLUT, LINC00354, TRPM1, ADAT1, KRT27, LIPE, GFY* and *EIF3L*) and five chromosomal regions (2p13, 4q31.2, 5q12, 13q34 and 20q13.2) identified in the present study have not been revealed to be associated with CAD or cardiovascular disease-related phenotypes in previous GWASs.

### Gene Ontology analysis of genes identified in the present study

Biological functions of the 21 genes identified in the present study were estimated using the database of Gene Ontology and GO Annotations (QuickGO; [Table VII](#tVII-br-0-0-1152){ref-type="table"}). Given that *FAM170B-AS1* is the gene for non-coding RNA, *FAM170B* was examined. Various biological functions were predicted in the 18 genes (*RNF2, YEATS2, USP45, ITGB8, TNS3, FAM170B, PRKG1, BTRC, MKI67, STIM1, OR52E4, MON2, TRPM1, ADAT1, KRT27, LIPE, GFY and EIF3L*), although those of *KIAA1551, PLUT* and *LINC00354* were not. Gene ontology analysis revealed that *ITGB8, PRKG1, STIM1* and *LIPE* may be involved in the development of CAD.

### Network analysis of newly identified genes

Network analysis of the 21 genes identified in the present study was performed using the GeneMANIA Cytoscape plugin with Cytoscape v3.4.0 software ([Figs. 1](#f1-br-0-0-1152){ref-type="fig"} and [2](#f2-br-0-0-1152){ref-type="fig"}). FAM170B was applied to the analysis instead of *FAM170B-AS1*. *PLUT* and *LINC00354* were not included in the GeneMANIA database. *GFY* had no interaction with other genes. The network analysis revealed that the 18 genes identified in the present study had potential direct or indirect interactions with the 30 genes previously revealed to be associated with CAD ([Fig. 1](#f1-br-0-0-1152){ref-type="fig"}). Similar analysis revealed that complex networks were observed between the 18 genes identified in the present study and the 228 genes identified in previous GWASs ([Fig. 2](#f2-br-0-0-1152){ref-type="fig"}).

Discussion
==========

Despite recent advances in therapy for acute coronary syndrome, including coronary stent implantation ([@b49-br-0-0-1152]), CAD remains the leading cause of mortality and is therefore a key public health problem ([@b4-br-0-0-1152]). The identification of genetic variants that confer susceptibility to CAD is therefore clinically important for the prevention and management of this condition.

The EWAS was performed for patients with early-onset CAD, with genetic factors serving a greater role in such patients compared with those with late-onset CAD. The present study identified the 54 SNPs as significant and independent determinants of CAD. These SNPs together accounted for 15.5% of the cause of CAD. Among these loci, 21 genes (*RNF2, YEATS2, USP45, ITGB8, TNS3, FAM170B-AS1, PRKG1, BTRC, MKI67, STIM1, OR52E4, KIAA1551, MON2, PLUT, LINC00354, TRPM1, ADAT1, KRT27, LIPE, GFY* and *EIF3L*) and 5 chromosomal regions (2p13, 4q31.2, 5q12, 13q34 and 20q13.2) that confer susceptibility to CAD have been newly identified.

Among 26 SNPs identified, 14 SNPs were significantly associated with two to five of the eight intermediate phenotypes. The SNP rs9466 of *EIF3L* was associated with hypertension, DM, hypertriglyceridemia, hyper-LDL-cholesterolemia and hyperuricemia; rs11823828 of *OR52E4* with hypertension, DM, hypertriglyceridemia, and CKD; rs11174549 of *MON2* with hypertension, DM, hyper-LDL-cholesterolemia; rs10514995 at 5q12 with hypertension, DM and hyperuricemia; rs1046592 of *RNF2* and rs13427905 at 2p13 with hypertension and DM; rs6067640 at 20q13.2 with hypertension and hypo-HDL-cholesterolemia; rs7333181 at 13q34 with DM and hypertriglyceridemia; rs10771894 of *KIAA155*1 with DM and hypo-HDL-cholesterolemia; rs954750 of *PLUT* with DM and CKD; rs34052647 of *LIPE* with hypertriglyceridemia and hyperuricemia; rs145121731 of *MKI67* with hypo-HDL-cholesterolemia and CKD; rs41288947 of *USP45* and rs9414827 of *PRKG1* with hypo-HDL-cholesterolemia and obesity. The seven SNPs were significantly related to one of the eight intermediate phenotypes. The rs73053944 of *GFY* was associated with hypertension; rs145161932 of *ADAT1* with DM; rs76174573 of *YEATS2* with hypertriglyceridemia; rs80015015 of *ITGB8* with hypo-HDL-cholesterolemia; rs4907518 of *LINC00354* and rs6537384 at 4q31.2 with hyper-LDL-cholesterolemia; rs17558532 of *KRT27* with CKD. Given that these intermediate phenotypes are risk factors for CAD ([@b4-br-0-0-1152]), the association between these loci and CAD may be attributable, at least in part, to their effects on intermediate phenotypes. By contrast, five SNPs in *TNS3, FAM170B-AS1, BTRC, STIM1* and *TRPM1* were not associated with intermediate phenotypes. The underlying molecular mechanisms of the association between these loci and CAD remain to be elucidated.

Recent GWASs have identified potential biological pathways underlying the association between genetic loci and CAD, including metabolism of LDL-cholesterol, triglycerides and lipoprotein (a); insulin resistance; thrombosis; inflammation, cell adhesion and transendothelial migration; cellular proliferation, vascular remodeling and extracellular matrix metabolism; and vascular tone and nitric oxide signaling ([@b50-br-0-0-1152],[@b51-br-0-0-1152]). Network analysis of functional gene-gene interactions may be informative to clarify biological process of CAD and to identify therapeutic targets for this condition ([@b52-br-0-0-1152]). Therefore, the present study performed gene ontology and network analyses to predict biological processes of the identified genes and interactions between these genes and those previously revealed to be associated with CAD. Gene ontology analysis revealed that biological functions of *ITGB8* (integrin-mediated signaling pathway), *PRKG1* (relaxation of vascular smooth muscle), *STIM1* (activation of store-operated calcium channel activity) and *LIPE* (cholesterol and triglyceride metabolism) may serve roles in the development of CAD. However, the roles of the remaining 17 genes in CAD remain unclear. The network analysis revealed that the 18 genes identified in the present study had direct or indirect interactions with the 30 genes selected from the DisGeNET database ([@b47-br-0-0-1152],[@b48-br-0-0-1152]), as well as complex networks with 228 genes previously identified by the GWASs ([@b7-br-0-0-1152]). However, the underlying molecular mechanisms of these interactions remain to be elucidated.

It was previously demonstrated that six SNPs were associated with CAD (P\<0.01), as determined by multivariable logistic regression analysis with adjustment for covariates following an initial EWAS screening of allele frequencies among subjects with early-onset and late-onset forms of this condition ([@b33-br-0-0-1152]). The associations between three of the six SNPs \[rs202069030 (P=2.58×10^−6^), rs7188 (P=0.0098) and rs2271395 (P=0.0042)\] and CAD were replicated (P\<0.05) in the present study. These results suggested that genetic variants associated with CAD differ, in part, between early-onset and late-onset patients with this condition. We also examined nine SNPs associated with MI (P\<0.01) in a previous study ([@b33-br-0-0-1152]). Associations between five of the nine SNPs \[rs202103723 (P=0.0033), rs188212047 (P=0.0034), rs1265110 (P=2.69×10^−5^), rs9258102 (P=0.0374) and rs439121 (P=0.0108)\] and CAD (P\<0.05) were identified in the present study.

There are several limitations to the present study: i) Given that the results were not replicated, their validation will be necessary in independent study populations or in other ethnic groups; ii) it is possible that SNPs identified in the present study are in LD with other genetic variants in the same gene or in other nearby genes that are actually responsible for the development of CAD; and iii) the functional relevance of identified SNPs to the pathogenesis of CAD remains to be elucidated.

In conclusion, the present study identified the 54 SNPs as significant and independent determinants of CAD. Among these loci, 21 genes (*RNF2, YEATS2, USP45, ITGB8, TNS3, FAM170B-AS1, PRKG1, BTRC, MKI67, STIM1, OR52E4, KIAA1551, MON2, PLUT, LINC00354, TRPM1, ADAT1, KRT27, LIPE, GFY* and *EIF3L*) and 5 chromosomal regions (2p13, 4q31.2, 5q12, 13q34 and 20q13.2) that confer susceptibility to CAD were newly identified in the present study. Determination of genotypes for the SNPs at these loci may prove informative for assessment of the genetic risk for CAD in Japanese patients.
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###### 

Characteristics of control subjects and patients with coronary artery disease.

  Characteristic                   Control       Coronary artery disease   P-value
  -------------------------------- ------------- ------------------------- ----------
  No. subjects                     5,774         1,482                     
  Age, years                         50.6±10.2   55.9±7.4                  \<0.0001
  Sex, males/females, %            52.1/47.9     82.5/17.5                 \<0.0001
  Smoking, %                       42.5          43.0                        0.7719
  Obesity, %                       31.0          43.0                      \<0.0001
  Body mass index, kg/m^2^         23.2±3.5      24.5±3.5                  \<0.0001
  Hypertension, %                  31.7          70.0                      \<0.0001
  Systolic BP, mmHg                121±18        139±27                    \<0.0001
  Diastolic BP, mmHg                 75±13         78±15                   \<0.0001
  Diabetes mellitus, %             12.7          58.7                      \<0.0001
  Fasting plasma glucose, mmol/l     5.66±1.78     7.55±3.39               \<0.0001
  Blood hemoglobin A~1c~, %          5.72±0.96     6.89±1.75               \<0.0001
  Dyslipidemia, %                  56.9          84.1                      \<0.0001
  Serum triglycerides, mmol/l        1.32±0.98     1.84±1.34               \<0.0001
  Serum HDL-cholesterol, mmol/l      1.65±0.45     1.20±0.36               \<0.0001
  Serum LDL-cholesterol, mmol/l      3.18±0.83     3.18±0.98                 0.9770
  Chronic kidney disease, %        10.3          29.4                      \<0.0001
  Serum creatinine, µmol/l           69.8±61.0     95.5±119.3              \<0.0001
  eGFR, ml min^−1^ 1.73 m^−2^        78.7±17.1     70.7±26.9               \<0.0001
  Hyperuricemia, %                 15.2          25.5                      \<0.0001
  Serum uric acid, µmol/l          321±89          353±102                 \<0.0001

Quantitative data represent the mean ± standard deviation and were compared between subjects with coronary artery disease and controls with the unpaired Student\'s t-test. Categorical data were compared between the two groups using Pearson\'s χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference. Obesity was defined as a body mass index of ≥25 kg/m2; hypertension as a systolic BP of ≥140 mmHg, diastolic BP of ≥90 mmHg, or the taking of anti-hypertensive medication; diabetes mellitus as a fasting plasma glucose level of ≥6.93 mmol/l, blood hemoglobin A1c content of ≥6.5%, or the taking of anti-diabetes medication; dyslipidemia as a serum triglyceride concentration of ≥1.65 mmol/l, serum HDL-cholesterol concentration of \<1.04 mmol/l, serum LDL-cholesterol concentration of ≥3.64 mmol/l or the taking of anti-dyslipidemic medication; chronic kidney disease as an estimated glomerular filtration rate (eGFR) of \<60 ml min^−1^ 1.73 m^−2^; and hyperuricemia as a serum uric acid concentration of \>416 µmol/l or the taking of uric acid-lowering medication. BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

170 SNPs significantly (FDR \<0.5) associated with coronary artery disease in the exome-wide association study.

  Gene             SNP           Nucleotide substitution^[a](#tfn3-br-0-0-1152){ref-type="table-fn"}^   Amino acid substitution   Chromosome   Position    MAF, %   Allele OR   P-value, allele frequency   FDR, allele frequency
  ---------------- ------------- ---------------------------------------------------------------------- ------------------------- ------------ ----------- -------- ----------- --------------------------- -----------------------
  *PLCB2*          rs200787930   C/T                                                                    E1106K                    15           40289298    1.2      0.03        1.24×10^−29^                1.56×10^−26^
  *MARCH1*         rs61734696    G/T                                                                    Q137K                     4            164197303   1.2      0.03        2.09×10^−29^                2.54×10^−26^
  *VPS33B*         rs199921354   C/T                                                                    R80Q                      15           91013841    1.2      0.03        2.76×10^−29^                3.30×10^−26^
  *CXCL8*          rs188378669   G/T                                                                    E31\*                     4            73741568    1.2      0.03        3.15×10^−29^                3.70×10^−26^
  *TMOD4*          rs115287176   G/A                                                                    R277W                     1            151170961   1.2      0.03        1.21×10^−28^                1.39×10^−25^
  *COL6A3*         rs146092501   C/T                                                                    E1386K                    2            237371861   1.2      0.04        2.93×10^−28^                3.27×10^−25^
  *ZNF77*          rs146879198   G/A                                                                    R340\*                    19           2934109     1.2      0.04        2.92×10^−28^                3.27×10^−25^
  *ADGRL3*         rs192210727   G/T                                                                    R580I                     4            61909615    1.3      0.10        2.92×10^−23^                3.06×10^−20^
  *OR52E4*         rs11823828    T/G                                                                    F227L                     11           5884973     36.6     1.54        3.40×10^−21^                3.35×10^−18^
  *ALDH2*          rs671         G/A                                                                    E504K                     12           111803962   27.6     1.41        4.12×10^−15^                3.78×10^−12^
  *ACAD10*         rs11066015    G/A                                                                                              12           111730205   27.5     1.41        4.92×10^−15^                4.45×10^−12^
  *BRAP*           rs3782886     A/G                                                                                              12           111672685   29.3     1.37        4.38×10^−13^                3.71×10^−10^
  *HECTD4*         rs11066280    T/A                                                                                              12           112379979   29.0     1.37        6.94×10^−13^                5.73×10^−10^
  *HECTD4*         rs2074356     C/T                                                                                              12           112207597   25.4     1.36        1.21×10^−11^                9.78×10^−9^
  *NAA25*          rs12231744    C/T                                                                    R876K                     12           112039251   35.1     0.77        1.68×10^−9^                 1.24×10^−6^
  *GOSR2*          rs1052586     T/C                                                                                              17           46941097    48.7     0.79        3.94×10^−8^                 2.61×10^−5^
  *ATXN2*          rs7969300     T/C                                                                    N248S                     12           111555908   38.8     0.79        4.41×10^−8^                 2.87×10^−5^
  *LILRB2*         rs73055442    C/T                                                                    R103H                     19           54279838    1.6      44.10       2.00×10^−7^                 1.20×10^−4^
                   rs12229654    T/G                                                                                              12           110976657   22.5     1.28        2.09×10^−7^                 1.24×10^−4^
  *LOC107987429*   rs2844533     T/C                                                                                              6            31383025    15.3     1.32        3.49×10^−7^                 1.95×10^−4^
  *MTFR2*          rs143974258   G/A                                                                    R360\*                    6            136231355   3.3      0.05        6.66×10^−7^                 3.60×10^−4^
  *PSORS1C1*       rs3130559     C/T                                                                                              6            31129524    44.2     0.82        1.51×10^−6^                 7.74×10^−4^
                   rs2596548     G/T                                                                                              6            31362769    5.4      1.51        1.83×10^−6^                 9.21×10^−4^
  *EIF3L*          rs9466        T/C                                                                                              22           37877742    21.6     1.28        1.96×10^−6^                 9.77×10^−4^
  *LPGAT1*         rs150552771   T/C                                                                    K200E                     1            211783358   5.0      7.14        2.26×10^−6^                 0.0011
  *LAIR2*          rs34429135    T/A                                                                    F115Y                     19           54508164    2.5      ND          2.70×10^−6^                 0.0013
                   rs2523644     A/G                                                                                              6            31374707    8.1      1.40        2.75×10^−6^                 0.0013
                   rs10757278    A/G                                                                                              9            22124478    49.5     0.83        2.92×10^−6^                 0.0014
  *CCHCR1*         rs130067      T/G                                                                    E328D                     6            31150734    33.2     0.81        3.10×10^−6^                 0.0015
  *TCHP*           rs74416240    G/A                                                                                              12           109904793   13.3     1.30        3.25×10^−6^                 0.0015
                   rs1333049     G/C                                                                                              9            22125504    49.4     1.20        3.95×10^−6^                 0.0018
  *CDKN2B-AS1*     rs4977574     A/G                                                                                              9            22098575    47.1     1.21        4.18×10^−6^                 0.0019
  *CDKN2B-AS1*     rs2383207     G/A                                                                                              9            22115960    33.7     0.81        4.86×10^−6^                 0.0022
  *SLC16A1*        rs1049434     T/A                                                                    D490E                     1            112913924   34.7     0.82        5.76×10^−6^                 0.0025
  *GIT2*           rs925368      T/C                                                                    N389S                     12           109953174   12.5     1.30        6.02×10^−6^                 0.0026
                   rs1333048     A/C                                                                                              9            22125348    49.6     1.20        6.46×10^−6^                 0.0028
                   rs2523578     T/C                                                                                              6            31360765    8.1      1.39        6.54×10^−6^                 0.0028
                   rs404890      G/T                                                                                              6            32231090    30.5     1.22        8.90×10^−6^                 0.0037
  *APOE*           rs7412        C/T                                                                    R176C                     19           44908822    4.3      0.60        1.06×10^−5^                 0.0043
  *CCHCR1*         rs130071      G/A                                                                                              6            31148433    5.1      1.52        1.06×10^−5^                 0.0043
                   rs602633      C/A                                                                                              1            109278889   7.6      0.69        1.15×10^−5^                 0.0046
  *CELSR2*         rs12740374    G/T                                                                                              1            109274968   7.7      0.69        1.15×10^−5^                 0.0046
  *MKI67*          rs145121731   G/A                                                                    S2722L                    10           128102595   1.5      2.04        1.20×10^−5^                 0.0047
  *CUBN*           rs78201384    C/T                                                                    E304K                     10           17111024    2.7      0.52        1.38×10^−5^                 0.0054
  *PSORS1C3*       rs887466      T/C                                                                                              6            31175734    41.1     1.20        1.38×10^−5^                 0.0054
  *PSORS1C1*       rs3094663     G/A                                                                                              6            31139310    30.9     1.20        1.40×10^−5^                 0.0054
                   rs10853110    A/G                                                                                              17           49241052    39.2     1.20        1.49×10^−5^                 0.0057
  *WDR37*          rs10794720    C/T                                                                                              10           1110225     8.5      0.71        1.52×10^−5^                 0.0057
  *CELSR2*         rs629301      A/C                                                                                              1            109275684   7.8      0.70        1.52×10^−5^                 0.0057
  *SKIV2L*         rs592229      G/T                                                                                              6            31962664    42.4     1.20        1.57×10^−5^                 0.0058
                   rs12182351    T/C                                                                                              6            32233930    29.8     1.22        1.59×10^−5^                 0.0059
  *POU5F1*         rs3130503     G/A                                                                                              6            31169388    29.5     1.20        1.64×10^−5^                 0.0060
  *PSORS1C3*       rs1265155     T/C                                                                                              6            31175917    41.1     1.19        1.68×10^−5^                 0.0061
  *CELSR2*         rs646776      A/G                                                                                              1            109275908     7.7    0.70        1.70×10^−5^                 0.0062
                   rs2596503     C/T                                                                                              6            31353033    19.3     1.24        1.75×10^−5^                 0.0063
  *TRPM1*          rs2241493     T/C                                                                    N54S                      15           31070149    12.6     0.76        1.81×10^−5^                 0.0065
  *CCDC141*        rs13419085    T/C                                                                    N1170S                    2            178837710     1.8    0.46        1.92×10^−5^                 0.0068
  *VARS2*          rs9394021     A/G                                                                    Q777R                     6            30925350    44.9     0.84        1.98×10^−5^                 0.0069
  *SFTA2*          rs2286655     T/C                                                                                              6            30931969    44.9     1.19        1.99×10^−5^                 0.0069
                   rs3873334     T/C                                                                                              6            30928370    44.9     1.19        1.98×10^−5^                 0.0069
                   rs9261800     C/G                                                                                              6            30408822      2.8    7.21        2.02×10^−5^                 0.0069
  *TCF19*          rs3130453     C/T                                                                                              6            31157072    34.4     0.83        2.10×10^−5^                 0.0072
  *C21orf59*       rs76974938    C/T                                                                    D67N                      21           32609946      2.4    0.00        2.14×10^−5^                 0.0073
  *DDR1*           rs2239518     T/C                                                                                              6            30897948    44.9     1.19        2.19×10^−5^                 0.0074
  *CDSN*           rs3130984     C/T                                                                    S143N                     6            31117187    13.4     1.29        2.20×10^−5^                 0.0074
                   rs197932      T/C                                                                                              17           46896981    26.9     0.82        2.23×10^−5^                 0.0075
  *CDSN*           rs3130981     C/T                                                                    D527N                     6            31116036    13.6     1.29        2.30×10^−5^                 0.0075
  *MICB-DT*        rs3132469     C/T                                                                                              6            31488790      5.3    1.46        2.41×10^−5^                 0.0078
  *HLA-DQB1*       rs1049056     C/A                                                                    A6S                       6            32666592    11.9     1.30        2.51×10^−5^                 0.0081
  *DDR1*           rs2239517     A/G                                                                                              6            30897338    44.6     1.19        2.59×10^−5^                 0.0083
  *CCHCR1*         rs1265110     G/A                                                                                              6            31151645    30.2     0.83        2.69×10^−5^                 0.0085
  *CCDC63*         rs10774610    T/C                                                                                              12           110902439   23.7     1.22        2.76×10^−5^                 0.0087
  *GTF2H4*         rs2284176     C/T                                                                                              6            30907845    44.6     1.19        2.80×10^−5^                 0.0088
  *GTF2H4*         rs3909130     G/A                                                                                              6            30906388    44.6     1.19        2.84×10^−5^                 0.0089
  *GTF2H4*         rs916920      G/A                                                                                              6            30909425    44.7     1.19        2.85×10^−5^                 0.0089
                   rs1264569     A/G                                                                                              6            30397543      4.6    1.49        2.98×10^−5^                 0.0092
  *CACNA1D*        rs35874056    G/A                                                                    G460S                     3            53702798      2.0    25.00       3.09×10^−5^                 0.0094
                   rs9468845     A/G                                                                                              6            30901816    44.7     1.19        3.12×10^−5^                 0.0094
  *DDR1*           rs8408        C/T                                                                                              6            30899889    44.7     1.19        3.11×10^−5^                 0.0094
  *DDR1*           rs7756521     C/T                                                                                              6            30880476    44.7     1.19        3.10×10^−5^                 0.0094
  *CDKN2B-AS1*     rs1011970     G/T                                                                                              9            22062135      5.6    1.41        3.15×10^−5^                 0.0095
  *ADAT1*          rs145161932   T/C                                                                    R57G                      16           75612670      1.4    0.39        3.29×10^−5^                 0.0098
  *POU5F1*         rs885950      T/G                                                                                              6            31172375    34.0     0.83        3.28×10^−5^                 0.0098
  *DDR1*           rs4618569     A/G                                                                                              6            30887474    44.7     1.19        3.41×10^−5^                 0.0101
  *KRT13*          rs146918776   A/G                                                                    Y281H                     17           41502993      1.5    1.94        3.51×10^−5^                 0.0103
                   rs2523638     G/A                                                                                              6            31376496    43.1     1.19        3.53×10^−5^                 0.0103
  *PSRC1*          rs599839      A/G                                                                                              1            109279544     7.9    0.71        3.52×10^−5^                 0.0103
                   rs9275141     G/T                                                                                              6            32683340    26.4     1.21        3.62×10^−5^                 0.0105
  *CCDC63*         rs10849915    T/C                                                                                              12           110895818   23.6     1.22        3.63×10^−5^                 0.0105
  *HLA-DRA*        rs3177928     G/A                                                                                              6            32444658      5.9    1.41        3.81×10^−5^                 0.0108
  *OAS3*           rs2072134     C/T                                                                                              12           112971371   17.6     1.24        4.06×10^−5^                 0.0114
  *USP45*          rs41288947    C/G                                                                    T521R                     6            99446210    14.9     1.26        4.11×10^−5^                 0.0115
  *CCHCR1*         rs1265109     A/C                                                                                              6            31151812    48.2     1.18        4.16×10^−5^                 0.0116
  *LOC101929163*   rs6930777     C/T                                                                                              6            32383789      5.5    1.43        4.45×10^−5^                 0.0122
                   rs7333181     G/A                                                                                              13           111568950     2.5    0.54        4.45×10^−5^                 0.0122
  *DDR1*           rs1264323     T/C                                                                                              6            30888130    38.8     1.19        4.48×10^−5^                 0.0122
  *LINC00243*      rs3094111     G/A                                                                                              6            30820414    14.7     1.25        4.52×10^−5^                 0.0123
                   rs10484561    T/G                                                                                              6            32697643      5.9    1.41        4.55×10^−5^                 0.0123
  *PSORS1C1*       rs3130558     G/C                                                                                              6            31129406    13.7     1.27        4.59×10^−5^                 0.0124
  *HLA-DQB1*       rs1049060     T/A                                                                    S27T                      6            32666529    28.8     1.20        4.92×10^−5^                 0.0131
                   rs2844650     G/A                                                                                              6            30934756      4.7    1.47        4.99×10^−5^                 0.0131
  *DDR1*           rs3132572     T/C                                                                                              6            30893952      4.7    1.47        4.99×10^−5^                 0.0131
  *CCHCR1*         rs1265115     T/G                                                                                              6            31149298    47.7     1.18        4.96×10^−5^                 0.0131
  *CCHCR1*         rs3094225     T/C                                                                                              6            31145275    48.4     1.18        4.93×10^−5^                 0.0131
  *LOC107987453*   rs3129987     C/T                                                                                              6            30798427    14.5     1.25        5.05×10^−5^                 0.0132
  *DPCR1*          rs2517451     A/G                                                                                              6            30946974      4.7    1.47        5.11×10^−5^                 0.0133
  *KIAA1551*       rs10771894    A/G                                                                    S352G                     12           31982009    32.4     1.19        5.18×10^−5^                 0.0134
                   rs13427905    C/T                                                                                              2            71846585    18.5     0.80        5.22×10^−5^                 0.0134
  *ABCA1*          rs1883025     G/A                                                                                              9            104902020   28.8     0.83        5.46×10^−5^                 0.0139
  *SFTA2*          rs2253705     G/A                                                                                              6            30932317    18.0     1.23        5.60×10^−5^                 0.0141
  *PLUT*           rs954750      G/A                                                                                              13           27889801    48.3     1.18        5.86×10^−5^                 0.0146
  *TCF19*          rs1419881     T/C                                                                                              6            31162816    48.1     1.18        6.37×10^−5^                 0.0156
                   rs13209234    G/A                                                                                              6            32448198      5.9    1.41        6.47×10^−5^                 0.0158
  *PSORS1C1*       rs1265100     T/C                                                                                              6            31137533    32.2     0.83        6.55×10^−5^                 0.0159
  *YEATS2*         rs76174573    G/T                                                                    C1232F                    3            183804099     3.7    0.61        6.74×10^−5^                 0.0162
  *ABO*            rs1053878     C/T                                                                    P156L                     9            133256264   22.8     1.20        6.78×10^−5^                 0.0162
                   rs4014195     C/G                                                                                              11           65739351    16.6     1.24        6.78×10^−5^                 0.0162
  *SFTA2*          s2253588      C/G                                                                                              6            30931600    23.6     1.21        6.93×10^−5^                 0.0165
  *CYP4F8*         rs201166643   C/A                                                                    R488S                     19           15629257      1.1    ND          7.00×10^−5^                 0.0165
  *NAXE*           rs7516274     C/G                                                                    L19V                      1            156591859     1.8    0.48        7.18×10^−5^                 0.0169
                   rs10757283    T/C                                                                                              9            22134173    33.8     0.84        7.25×10^−5^                 0.0170
  *BTNL2*          rs28362680    G/A                                                                    A202V                     6            32403039    39.7     0.85        7.40×10^−5^                 0.0171
  *BTNL2*          rs10947262    C/T                                                                                              6            32405535    39.7     0.85        7.40×10^−5^                 0.0171
  *KRT27*          rs17558532    C/T                                                                    A284T                     17           40779624      3.6    0.62        7.71×10^−5^                 0.0176
  *GTF2H4*         rs3130780     G/T                                                                                              6            30906531    18.0     1.23        7.71×10^−5^                 0.0176
                   rs2532934     T/C                                                                                              6            30926982    24.1     1.20        7.74×10^−5^                 0.0176
  *VARS2*          rs753725      G/A                                                                                              6            30923094    24.1     1.20        7.68×10^−5^                 0.0176
  *PLUT*           rs11619319    A/G                                                                                              13           27913462    48.1     1.18        7.64×10^−5^                 0.0176
                   rs3095273     C/T                                                                                              6            29598592      5.5    1.41        8.16×10^−5^                 0.0184
  *TNS1*           rs918949      C/T                                                                    V1590I                    2            217809974   42.8     0.85        8.39×10^−5^                 0.0188
  *LINC00243*      rs3130785     C/T                                                                                              6            30828961    14.6     1.24        8.37×10^−5^                 0.0188
  *VARS2*          rs2249464     C/T                                                                    R309W                     6            30920384    24.1     1.20        9.39×10^−5^                 0.0207
                   rs3095345     A/G                                                                                              6            30854636    17.9     1.22        9.37×10^−5^                 0.0207
  *ITGB8*          rs80015015    G/A                                                                    C481Y                     7            20401881      7.1    1.35        1.01×10^−4^                 0.0220
  *VARS2*          rs885905      C/T                                                                                              6            30922654    23.4     1.20        1.07×10^−4^                 0.0232
  *LIPE*           rs34052647    G/A                                                                    R611C                     19           42407617      5.5    1.39        1.16×10^−4^                 0.0249
  *PHACTR1*        rs9369640     A/C                                                                                              6            12901209      9.1    0.74        1.30×10^−4^                 0.0275
  *BTNL2*          rs41417449    T/C                                                                    M295V                     6            32396234    23.0     0.83        1.35×10^−4^                 0.0280
  *BTNL2*          rs41441651    C/T                                                                    D336N                     6            32396111    23.0     0.83        1.35×10^−4^                 0.0280
  *BTNL2*          rs28362675    C/A                                                                    E454\*                    6            32394744    23.0     0.83        1.35×10^−4^                 0.0280
  *BTNL2*          rs78587369    G/A                                                                    T165I                     6            32403150    23.0     0.83        1.35×10^−4^                 0.0280
  *BTNL2*          rs3763315     G/T                                                                                              6            32408877    23.0     0.83        1.35×10^−4^                 0.0280
  *BTNL2*          rs2076528     T/G                                                                                              6            32396417    23.0     0.83        1.35×10^−4^                 0.0280
  *PRKG1*          rs9414827     G/A                                                                                              10           51137314    10.1     0.76        1.37×10^−4^                 0.0282
                   rs6537384     T/G                                                                                              4            145949613   28.8     1.19        1.43×10^−4^                 0.0294
                   rs6067640     G/A                                                                                              20           51092837    38.5     0.85        1.48×10^−4^                 0.0302
                   rs10514995    A/G                                                                                              5            66443611    48.7     1.16        1.51×10^−4^                 0.0306
  *BTNL2*          rs34423804    T/A                                                                    V283D                     6            32396269    23.0     0.83        1.63×10^−4^                 0.0329
  *PHACTR1*        rs9349379     G/A                                                                                              6            12903725    34.2     0.85        1.69×10^−4^                 0.0341
  *STIM1*          rs116855870   A/G                                                                                              11           4055527       1.1    1.93        1.71×10^−4^                 0.0343
  *ZNF142*         rs3821033     C/T                                                                    A1313T                    2            218642579   11.2     1.26        1.78×10^−4^                 0.0355
  *LINC00354*      rs4907518     G/A                                                                                              13           111898209   45.6     0.85        1.82×10^−4^                 0.0362
  *TNS3*           rs11763932    G/A                                                                                              7            47567880    42.0     0.85        1.91×10^−4^                 0.0378
  *BTRC*           rs2270439     C/A                                                                    P566H                     10           101550817     3.5    0.63        1.94×10^−4^                 0.0381
  *MIA3*           rs2936051     A/G                                                                    E881G                     1            222629862   40.1     0.85        1.96×10^−4^                 0.0384
                   rs6825911     C/T                                                                                              4            110460482   45.9     0.86        2.01×10^−4^                 0.0391
  *VNN1*           rs2294757     G/A                                                                    T26I                      6            132713959   37.4     0.85        2.02×10^−4^                 0.0393
  *ZNF860*         rs140232911   C/T                                                                    S161L                     3            31989561    10.4     0.44        2.09×10^−4^                 0.0406
                   rs838880      C/T                                                                                              12           124777047   47.5     1.16        2.23×10^−4^                 0.0430
  *MIA3*           rs2936052     A/G                                                                    K605R                     1            222629034   34.4     0.85        2.26×10^−4^                 0.0430
  *DTNBP1*         rs2743868     G/A                                                                                              6            15625577    31.6     1.18        2.26×10^−4^                 0.0430
  *MON2*           rs11174549    A/G                                                                    I1385V                    12           62565357      5.0    1.40        2.26×10^−4^                 0.0430
                   rs507666      G/A                                                                                              9            136149399   27.8     1.18        2.26×10^−4^                 0.0430
  *FAM170B*        rs73302786    G/T                                                                    D252E                     10           49131709      3.5    1.47        2.36×10^−4^                 0.0445
  *PSORS1C3*       rs3131018     G/T                                                                                              6            31175805    15.7     1.23        2.36×10^−4^                 0.0445
  *PIEZO2*         rs35033671    C/A                                                                    C1148F                    18           10759842    11.0     1.27        2.39×10^−4^                 0.0448
  *SLC22A3*        rs1810126     C/T                                                                                              6            160451119   49.1     0.86        2.46×10^−4^                 0.0460
  *PANK1*          rs11185790    G/A                                                                                              10           89612776    46.9     1.16        2.57×10^−4^                 0.0481
  *GFY*            rs73053944    C/G                                                                    T203S                     19           49427038      2.9    1.51        2.58×10^−4^                 0.0481
  *RNF2*           rs1046592     A/G                                                                                              1            185100429   33.9     0.85        2.63×10^−4^                 0.0488

Allele frequencies were analyzed using Fisher\'s exact test.

Major allele/minor allele. SNP, single nucleotide polymorphisms; MAF, minor allele frequency; OR, odds ratio; FDR, false discovery rate; ND, not determined.

###### 

162 SNPs associated with coronary artery disease as determined by multivariable logistic regression analysis.

                                       Dominant model   Recessive model                                  
  ---------------- ------------- ----- ---------------- ----------------- ------------ ---------- ------ ------------
  *PLCB2*          rs200787930   C/T   \<0.0001         0.02              0.01--0.09                     
  *MARCH1*         rs61734696    G/T   \<0.0001         0.02              0.01--0.10                     
  *VPS33B*         rs199921354   C/T   \<0.0001         0.02              0.01--0.09                     
  *CXCL8*          rs188378669   G/T   \<0.0001         0.02              0.01--0.09                     
  *TMOD4*          rs115287176   G/A   \<0.0001         0.02              0.01--0.10                     
  *COL6A3*         rs146092501   C/T   \<0.0001         0.02              0.01--0.10                     
  *ZNF77*          rs146879198   G/A   \<0.0001         0.02              0.01--0.10                     
  *ADGRL3*         rs192210727   G/T   \<0.0001         0.07              0.03--0.16     0.9959          
  *OR52E4*         rs11823828    T/G   \<0.0001         1.66              1.41--1.97   \<0.0001   2.44   2.01--2.97
  *ALDH2*          rs671         G/A   \<0.0001         1.73              1.50--2.01   \<0.0001   1.80   1.44--2.26
  *ACAD10*         rs11066015    G/A   \<0.0001         1.73              1.49--2.01   \<0.0001   1.79   1.42--2.25
  *BRAP*           rs3782886     A/G   \<0.0001         1.71              1.48--1.99   \<0.0001   1.70   1.36--2.12
  *HECTD4*         rs11066280    T/A   \<0.0001         1.73              1.49--2.01   \<0.0001   1.73   1.38--2.17
  *HECTD4*         rs2074356     C/T   \<0.0001         1.61              1.39--1.87   \<0.0001   1.76   1.38--2.26
  *NAA25*          rs12231744    C/T   \<0.0001         0.63              0.54--0.73   \<0.0001   0.55   0.43--0.70
  *GOSR2*          rs1052586     T/C     0.0003         0.73              0.62--0.87   \<0.0001   0.64   0.53--0.77
  *ATXN2*          rs7969300     T/C   \<0.0001         0.63              0.55--0.74   \<0.0001   0.57   0.45--0.71
                   rs12229654    T/G   \<0.0001         1.46              1.26--1.69   \<0.0001   1.72   1.31--2.25
  *LOC107987429*   rs2844533     T/C   \<0.0001         1.36              1.17--1.59     0.8616          
  *MTFR2*          rs143974258   G/A     0.0014         0.04              0.01--0.28                     
  *PSORS1C1*       rs3130559     C/T     0.0127         0.82              0.70--0.96     0.0629          
                   rs2596548     G/T   \<0.0001         1.76              1.41--2.20     0.2047          
  *EIF3L*          rs9466        T/C     0.0053         1.24              1.07--1.44     0.0199   1.47   1.06--2.04
  *LPGAT1*         rs150552771   T/C     0.9970                                        \<0.0001   2.20   1.83--2.64
                   rs2523644     A/G   \<0.0001         1.59              1.31--1.92     0.9088          
                   rs10757278    A/G   \<0.0001         0.71              0.60--0.83     0.0023   0.77   0.65--0.91
  *CCHCR1*         rs130067      T/G     0.0010         0.78              0.68--0.91     0.0183   0.73   0.57--0.95
  *TCHP*           rs74416240    G/A     0.0002         1.35              1.15--1.58     0.1725          
                   rs1333049     G/C     0.0031         1.29              1.09--1.53   \<0.0001   1.41   1.20--1.66
  *CDKN2B-AS1*     rs4977574     A/G     0.0003         1.36              1.15--1.60   \<0.0001   1.43   1.21--1.69
  *CDKN2B-AS1*     rs2383207     G/A   \<0.0001         0.75              0.65--0.87     0.0171   0.75   0.59--0.95
  *SLC16A1*        rs1049434     T/A     0.0106         0.83              0.71--0.96   \<0.0001   0.57   0.45--0.73
  *GIT2*           rs925368      T/C     0.0001         1.37              1.16--1.61     0.3189          
                   rs1333048     A/C     0.0036         1.29              1.09--1.53   \<0.0001   1.40   1.19--1.64
                   rs2523578     T/C   \<0.0001         1.55              1.27--1.88     0.8694          
                   rs404890      G/T     0.0005         1.29              1.12--1.50     0.0160   1.35   1.06--1.72
  *APOE*           rs7412        C/T     0.0001         0.56              0.42--0.76     0.2259          
  *CCHCR1*         rs130071      G/A     0.0149         1.36              1.06--1.73     0.2668          
                   rs602633      C/A     0.0001         0.64              0.51--0.80     0.1782          
  *CELSR2*         rs12740374    G/T   \<0.0001         0.63              0.51--0.79     0.1708          
  *MKI67*          rs145121731   G/A     0.0014         1.94              1.29--2.91     0.9957          
  *CUBN*           rs78201384    C/T     0.0003         0.50              0.34--0.73     0.9959          
  *PSORS1C3*       rs887466      T/C     0.0013         1.29              1.11--1.52     0.1666          
  *PSORS1C1*       rs3094663     G/A   \<0.0001         1.41              1.21--1.63     0.6404          
                   rs10853110    A/G     0.0026         1.26              1.09--1.47     0.0102   1.29   1.06--1.56
  *WDR37*          rs10794720    C/T     0.0003         0.68              0.55--0.84     0.0734          
  *CELSR2*         rs629301      A/C     0.0002         0.65              0.52--0.82     0.1708          
  *SKIV2L*         rs592229      G/T     0.0154         1.22              1.04--1.42     0.0138   1.26   1.05--1.51
                   rs12182351    T/C     0.0008         1.28              1.11--1.48     0.0138   1.37   1.07--1.75
  *POU5F1*         rs3130503     G/A   \<0.0001         1.41              1.22--1.63     0.6308          
  *PSORS1C3*       rs1265155     T/C     0.0017         1.29              1.10--1.50     0.1666          
  *CELSR2*         rs646776      A/G     0.0002         0.65              0.52--0.82   0.2660            
                   rs2596503     C/T     0.0204         1.19              1.03--1.38   0.1828            
  *TRPM1*          rs2241493     T/C     0.0002         0.71              0.60--0.85   0.0410     0.49   0.25--0.97
  *CCDC141*        rs13419085    T/C     0.0005         0.43              0.27--0.69                     
  *VARS2*          rs9394021     A/G     0.0261         0.82              0.69--0.98   0.0117     0.81   0.69--0.95
  *SFTA2*          rs2286655     T/C     0.0097         1.24              1.05--1.45   0.0277     1.22   1.02--1.45
                   rs3873334     T/C     0.0117         1.23              1.05--1.44   0.0261     1.22   1.02--1.45
  *TCF19*          rs3130453     C/T     0.0077         0.82              0.71--0.95   0.0024     0.68   0.53--0.87
  *DDR1*           rs2239518     T/C     0.0103         1.23              1.05--1.45   0.0282     1.22   1.02--1.45
  *CDSN*           rs3130984     C/T   \<0.0001         1.39              1.18--1.64   0.1220            
                   rs197932      T/C     0.0042         0.81              0.70--0.93   0.0348     0.73   0.54--0.98
  *CDSN*           rs3130981     C/T   \<0.0001         1.39              1.18--1.64   0.1226            
  *MICB-DT*        rs3132469     C/T   \<0.0001         1.63              1.30--2.05   0.3960            
  *HLA-DQB1*       rs1049056     C/A     0.0050         1.28              1.08--1.52   0.1586            
  *DDR1*           rs2239517     A/G     0.0115         1.23              1.05--1.44   0.0326     1.21   1.02--1.44
  *CCHCR1*         rs1265110     G/A     0.0096         0.83              0.71--0.95   0.0948            
  *CCDC63*         rs10774610    T/C     0.0006         1.29              1.12--1.49   0.0214     1.38   1.05--1.82
  *GTF2H4*         rs2284176     C/T     0.0153         1.22              1.04--1.43   0.0306     1.21   1.02--1.45
  *GTF2H4*         rs3909130     G/A     0.0138         1.22              1.04--1.43   0.0326     1.21   1.02--1.44
  *GTF2H4*         rs916920      G/A     0.0139         1.22              1.04--1.43   0.0326     1.21   1.02--1.44
                   rs1264569     A/G     0.0004         1.54              1.21--1.97   0.5339            
                   rs9468845     A/G     0.0141         1.22              1.04--1.43   0.0332     1.21   1.02--1.44
  *DDR1*           rs8408        C/T     0.0141         1.22              1.04--1.43   0.0326     1.21   1.02--1.44
  *DDR1*           rs7756521     C/T     0.0155         1.22              1.04--1.43   0.0303     1.21   1.02--1.45
  *CDKN2B-AS1*     rs1011970     G/T     0.0047         1.36              1.10--1.69   0.2199            
  *ADAT1*          rs145161932   T/C     0.0104         0.48              0.27--0.84   0.9960            
  *POU5F1*         rs885950      T/G     0.0049         0.81              0.70--0.94   0.0129     0.73   0.57--0.94
  *DDR1*           rs4618569     A/G     0.0141         1.22              1.04--1.43   0.0333     1.21   1.02--1.44
  *KRT13*          rs146918776   A/G   \<0.0001         2.21              1.50--3.26                     
                   rs2523638     G/A     0.0197         1.20              1.03--1.41   0.1032            
  *PSRC1*          rs599839      A/G     0.0004         0.67              0.54--0.83   0.1023            
                   rs9275141     G/T     0.0134         1.20              1.04--1.39   0.0065     1.43   1.11--1.85
  *CCDC63*         rs10849915    T/C     0.0005         1.30              1.12--1.50   0.0458     1.33   1.01--1.76
  *HLA-DRA*        rs3177928     G/A   \<0.0001         1.58              1.27--1.96   0.7635            
  *OAS3*           rs2072134     C/T     0.0004         1.31              1.13--1.53   0.0268     1.51   1.05--2.16
  *USP45*          rs41288947    C/G     0.0002         1.35              1.15--1.58   0.1360            
  *CCHCR1*         rs1265109     A/C     0.0007         1.35              1.14--1.61   0.0334     1.20   1.01--1.41
  *LOC101929163*   rs6930777     C/T   \<0.0001         1.60              1.28--2.00   0.9815            
                   rs7333181     G/A     0.0219         0.64              0.44--0.94   0.9969            
  *DDR1*           rs1264323     T/C     0.0240         1.19              1.02--1.39   0.0423     1.22   1.01--1.48
  *LINC00243*      rs3094111     G/A     0.0061         1.24              1.06--1.45   0.5293            
                   rs10484561    T/G   \<0.0001         1.59              1.28--1.98   0.7637            
  *PSORS1C1*       rs3130558     G/C   \<0.0001         1.39              1.18--1.64   0.2712            
  *HLA-DQB1*       rs1049060     T/A     0.0676                                        0.0077     1.38   1.09--1.75
                   rs2844650     G/A   \<0.0001         1.66              1.30--2.11   0.4729            
  *DDR1*           rs3132572     T/C   \<0.0001         1.66              1.30--2.11   0.4729            
  *CCHCR1*         rs1265115     T/G     0.0004         1.36              1.15--1.62   0.0443     1.19   1.00--1.40
  *CCHCR1*         rs3094225     T/C   \<0.0001         1.46              1.23--1.74   0.5822            
  *LOC107987453*   rs3129987     C/T     0.0037         1.26              1.08--1.47   0.5667            
  *DPCR1*          rs2517451     A/G   \<0.0001         1.65              1.30--2.11   0.4729            
  *CCHCR1*         rs1265115     T/G     0.0004         1.36              1.15--1.62   0.0443     1.19   1.00--1.40
  *CCHCR1*         rs3094225     T/C   \<0.0001         1.46              1.23--1.74   0.5822            
  *LOC107987453*   rs3129987     C/T     0.0037         1.26              1.08--1.47   0.5667            
  *DPCR1*          rs2517451     A/G   \<0.0001         1.65              1.30--2.11   0.4729            
  *KIAA1551*       rs10771894    A/G     0.1122                                        0.0085     1.35   1.08--1.69
                   rs13427905    C/T     0.0024         0.78              0.67--0.92   0.1397            
  *ABCA1*          rs1883025     G/A     0.0051         0.81              0.70--0.94   0.0080     0.68   0.51--0.90
  *SFTA2*          rs2253705     G/A     0.0015         1.28              1.10--1.48   0.6682            
  *PLUT*           rs954750      G/A     0.0409         1.19              1.01--1.41   0.0008     1.33   1.12--1.57
  *TCF19*          rs1419881     T/C     0.0009         1.34              1.13--1.60   0.0487     1.18   1.00--1.39
                   rs13209234    G/A   \<0.0001         1.55              1.25--1.93   0.7617            
  *PSORS1C1*       rs1265100     T/C     0.0055         0.81              0.70--0.94   0.4135            
  *YEATS2*         rs76174573    G/T     0.0031         0.61              0.44--0.85   0.1756            
  *ABO*            rs1053878     C/T     0.0033         1.25              1.08--1.44   0.1723            
                   rs4014195     C/G     0.0083         1.23              1.05--1.43   0.2586            
  *SFTA2*          rs2253588     C/G     0.0021         1.26              1.09--1.45   0.7016            
                   rs10757283    T/C     0.0079         0.82              0.71--0.95   0.0181     0.74   0.58--0.95
  *BTNL2*          rs28362680    G/A     0.1143                                        0.0082     0.76   0.62--0.93
  *BTNL2*          rs10947262    C/T     0.1143                                        0.0082     0.76   0.62--0.93
  *KRT27*          rs17558532    C/T     0.0004         0.57              0.41--0.78   0.5002            
  *GTF2H4*         rs3130780     G/T     0.0022         1.26              1.09--1.47   0.6706            
                   rs2532934     T/C     0.0023         1.25              1.08--1.45   0.5320            
  *VARS2*          rs753725      G/A     0.0021         1.26              1.09--1.45   0.5274            
  *PLUT*           rs11619319    A/G     0.0482         1.18              1.00--1.40   0.0007     1.33   1.13--1.58
                   rs3095273     C/T     0.0045         1.38              1.11--1.73   0.1778            
  *TNS1*           rs918949      C/T     0.0028         0.79              0.68--0.92   0.1301            
  *LINC00243*      rs3130785     C/T     0.0060         1.24              1.06--1.45   0.5417            
  *VARS2*          rs2249464     C/T     0.0028         1.25              1.08--1.44   0.5320            
                   rs3095345     A/G     0.0021         1.27              1.09--1.47   0.7469            
  *ITGB8*          rs80015015    G/A   \<0.0001         1.56              1.28--1.91   0.2511            
  *VARS2*          rs885905      C/T     0.0028         1.25              1.08--1.44   0.7687            
  *LIPE*           rs34052647    G/A     0.0001         1.53              1.23--1.90   0.0074     3.70   1.42--9.65
  *PHACTR1*        rs9369640     A/C     0.0025         0.73              0.60--0.90   0.1527            
  *BTNL2*          rs41417449    T/C     0.1641                                        0.0017     0.55   0.38--0.80
  *BTNL2*          rs41441651    C/T     0.1586                                        0.0017     0.55   0.38--0.80
  *BTNL2*          rs28362675    C/A     0.1584                                        0.0017     0.55   0.38--0.80
  *BTNL2*          rs78587369    G/A     0.1590                                        0.0018     0.55   0.38--0.80
  *BTNL2*          rs3763315     G/T     0.1637                                        0.0017     0.55   0.38--0.80
  *BTNL2*          rs2076528     T/G     0.1524                                        0.0017     0.55   0.38--0.80
  *PRKG1*          rs9414827     G/A     0.0003         0.70              0.58--0.85   0.0395     0.46   0.22--0.96
                   rs6537384     T/G     0.0191         1.19              1.03--1.38   0.1787            
                   rs6067640     G/A     0.0323         0.85              0.73--0.99   0.0054     0.74   0.60--0.91
                   rs10514995    A/G     0.0467         1.19              1.00--1.42   0.0825            
  *BTNL2*          rs34423804    T/A     0.1675                                        0.0018     0.55   0.38--0.80
  *PHACTR1*        rs9349379     G/A     0.0029         0.80              0.69--0.93   0.0820            
  *STIM1*          rs116855870   A/G     0.0133         1.76              1.13--2.76   0.9967            
  *ZNF142*         rs3821033     C/T     0.0015         1.32              1.11--1.57   0.3469            
  *LINC00354*      rs4907518     G/A     0.0138         0.82              0.70--0.96   0.0050     0.77   0.64--0.92
  *TNS3*           rs11763932    G/A     0.0054         0.81              0.69--0.94   0.0018     0.73   0.60--0.89
  *BTRC*           rs2270439     C/A     0.0063         0.64              0.47--0.88   0.6622            
  *MIA3*           rs2936051     A/G     0.1239                                        0.0002     0.67   0.55--0.83
                   rs6825911     C/T     0.0020         0.78              0.67--0.91   0.0446     0.83   0.70--1.00
  *VNN1*           rs2294757     G/A   0.2269                                          0.0334     0.79   0.63--0.98
  *ZNF860*         rs140232911   C/T   0.0013           0.14              0.04--0.46                     
                   rs838880      C/T   0.0338           1.20              1.01--1.41   0.0308     1.20   1.02--1.43
  *MIA3*           rs2936052     A/G   0.0927                                          0.0044     0.71   0.56--0.90
  *DTNBP1*         rs2743868     G/A   0.0208           1.19              1.03--1.37   0.0941            
  *MON2*           rs11174549    A/G   0.0427           1.28              1.01--1.61   0.1917            
                   rs507666      G/A   0.0098           1.21              1.05--1.40   0.1384            
  *FAM170B*        rs73302786    G/T   0.0003           1.62              1.25--2.11   0.6351            
  *PSORS1C3*       rs3131018     G/T   0.0002           1.35              1.15--1.58   0.9209            
  *PIEZO2*         rs35033671    C/A   0.0035           1.30              1.09--1.54   0.1909            
  *PANK1*          rs11185790    G/A   0.0065           1.26              1.07--1.48   0.0457     1.19   1.00--1.41
  *GFY*            rs73053944    C/G   0.0011           1.60              1.21--2.13   0.0698            
  *RNF2*           rs1046592     A/G   0.0301           0.85              0.74--0.98   0.7186            

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension, diabetes mellitus and dyslipidemia. P\<0.05 was considered to indicate a statistically significant difference. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

54 SNPs associated with coronary artery disease as determined by a stepwise forward selection procedure.

  Gene            SNP           P-value    R^2^ (individual)   R^2^ (accumulated)
  --------------- ------------- ---------- ------------------- --------------------
  *PLCB2*         rs200787930   \<0.0001   0.0297              0.0297
  *ALDH2*         rs671         \<0.0001   0.0061              0.0358
  *GOSR2*         rs1052586     \<0.0001   0.0053              0.0411
  *PSORS1C1*      rs3094663     \<0.0001   0.0052              0.0463
  *CCHCR1*        rs130071      \<0.0001   0.0059              0.0522
                  rs13427905    \<0.0001   0.0047              0.0569
  *OR52E4*        rs11823828    \<0.0001   0.0043              0.0612
  *EIF3L*         rs9466        \<0.0001   0.0042              0.0654
  *KIAA1551*      rs10771894    \<0.0001   0.0039              0.0693
  *CCDC141*       rs13419085    \<0.0001   0.0035              0.0728
  *MIA3*          rs2936051       0.0001   0.0033              0.0761
                  rs602633        0.0001   0.0033              0.0794
  *KRT27*         rs17558532      0.0001   0.0032              0.0826
  *TRPM1*         rs2241493       0.0002   0.0030              0.0856
                  rs7333181       0.0002   0.0030              0.0886
  *ADAT1*         rs145161932     0.0002   0.0029              0.0915
  *APOE*          rs7412          0.0003   0.0028              0.0943
  *YEATS2*        rs76174573      0.0004   0.0026              0.0969
  *SLC16A1*       rs1049434       0.0005   0.0025              0.0994
  *RNF2*          rs1046592       0.0007   0.0025              0.1019
                  rs6825911       0.0006   0.0024              0.1043
  *ITGB8*         rs80015015      0.0007   0.0024              0.1067
  *USP45*         rs41288947      0.0007   0.0024              0.1091
  *PHACTR1*       rs9369640       0.0007   0.0024              0.1115
                  rs1333048       0.0008   0.0024              0.1139
                  rs838880        0.0011   0.0022              0.1161
  *STIM1*         rs116855870     0.0017   0.0021              0.1182
                  rs2523644       0.0016   0.0021              0.1203
  *MKI67*         rs145121731   0.0020     0.0020              0.1223
  *FAM170B-AS1*   rs73302786    0.0019     0.0020              0.1243
                  rs6067640     0.0022     0.0020              0.1263
  *GFY*           rs73053944    0.0024     0.0019              0.1282
  *WDR37*         rs10794720    0.0033     0.0018              0.1300
  *SKIV2L*        rs592229      0.0037     0.0018              0.1318
                  rs6537384     0.0041     0.0017              0.1335
                  rs10757283    0.0058     0.0016              0.1351
  *CDKN2B-AS1*    rs1011970     0.0110     0.0014              0.1365
  *PRKG1*         rs9414827     0.0087     0.0014              0.1379
                  rs197932      0.0127     0.0013              0.1392
  *LINC00354*     rs4907518     0.0125     0.0013              0.1405
  *LIPE*          rs34052647    0.0151     0.0013              0.1418
  *BTRC*          rs2270439     0.0143     0.0013              0.1431
  *TNS3*          rs11763932    0.0163     0.0013              0.1444
  *TNS1*          rs918949      0.0158     0.0012              0.1456
                  rs12229654    0.0184     0.0011              0.1467
                  rs4014195     0.0213     0.0011              0.1478
  *PANK1*         rs11185790    0.0227     0.0011              0.1489
                  rs507666      0.0279     0.0010              0.1499
  *MON2*          rs11174549    0.0359     0.0009              0.1508
  *HECTD4*        rs2074356     0.0396     0.0009              0.1517
  *CUBN*          rs78201384    0.0484     0.0009              0.1526
  *PLUT*          rs954750      0.0497     0.0008              0.1534
  *ABCA1*         rs1883025     0.0479     0.0008              0.1542
                  rs10514995    0.0493     0.0008              0.1550

SNP, single nucleotide polymorphisms; R^2^, coefficient of determination.

###### 

Association between SNPs associated with coronary artery disease and intermediate phenotypes.

  Gene            SNP           Hypertension                                            DM                                                      Hyper-TG                                                Hypo-HDL                                                Hyper-LDL                                               CKD                                                     Obesity                                                 Hyperuricemia
  --------------- ------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  *PLCB2*         rs200787930   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0004^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.3432                                                  \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0405^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.9639
  *ALDH2*         rs671           0.0039^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0074^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0298^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0273^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0350^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
  *GOSR2*         rs1052586       0.3498                                                  0.0167^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.4457                                                    0.2898                                                  0.2638                                                  0.6185                                                0.3670                                                    0.4679
  *PSORS1C1*      rs3094663       0.0069^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0670                                                0.0947                                                    0.0020^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.3869                                                  0.1080                                                0.7345                                                    0.5091
  *CCHCR1*        rs130071        0.0865                                                  0.0008^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2247                                                    0.0143^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0141^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.5894                                                0.8651                                                    0.0423^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
                  rs13427905      0.0149^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0149^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.0524                                                    0.0545                                                  0.6318                                                  0.9487                                                0.1197                                                    0.0920
  *OR52E4*        rs11823828      0.0024^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0265^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.1186                                                  0.4445                                                  0.0027^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.1141                                                    0.2815
  *EIF3L*         rs9466          0.0008^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0204^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0054^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.2905                                                  0.0114^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.2368                                                0.2435                                                    0.0312^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
  *KIAA1551*      rs10771894      0.2439                                                  0.0091^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.9562                                                    0.0343^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.6934                                                  0.3869                                                0.0974                                                    0.5419
  *CCDC141*       rs13419085      0.3387                                                  0.1255                                                0.6537                                                    0.1647                                                  0.7447                                                  0.2483                                                0.8101                                                    0.7938
  *MIA3*          rs2936051       0.4092                                                  0.5246                                                0.9990                                                    0.0475^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.1222                                                  0.6614                                                0.8787                                                    0.1949
                  rs602633        0.4468                                                  0.2375                                                0.7350                                                    0.0005^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0021^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0842                                                0.6617                                                    0.9338
  *KRT27*         rs17558532      0.1706                                                  0.2358                                                0.3643                                                    0.3607                                                  0.7663                                                  0.0133^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2306                                                    0.5325
  *TRPM1*         rs2241493       0.3861                                                  0.2332                                                0.7465                                                    0.7106                                                  0.0815                                                  0.1387                                                0.5698                                                    0.9502
                  rs7333181       0.2308                                                  0.0487^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0379^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.1185                                                  0.2010                                                  0.0795                                                0.2182                                                    0.6544
  *ADAT1*         rs145161932     0.4468                                                  0.0160^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.3611                                                    0.3357                                                  0.5412                                                  0.7534                                                0.5836                                                    0.1202
  *APOE*          rs7412          0.3680                                                  0.9184                                                0.6322                                                    0.1157                                                \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.6367                                                0.5319                                                    0.2528
  *YEATS2*        rs76174573      0.1305                                                  0.0687                                                  0.0380^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0606                                                  0.8313                                                  0.6458                                                0.6338                                                    0.1706
  *SLC16A1*       rs1049434     0.8319                                                    0.0016^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.1897                                                    0.0686                                                0.9212                                                  0.0646                                                  0.8850                                                    0.2672
  *RNF2*          rs1046592       0.0007^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0140^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.5319                                                    0.0544                                                0.4098                                                  0.7276                                                  0.4643                                                    0.1040
                  rs6825911       0.0317^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.4070                                                  0.5755                                                    0.1068                                                0.1423                                                  0.4050                                                  0.2325                                                    0.6717
  *ITGB8*         rs80015015    0.4001                                                  0.5178                                                  0.4838                                                    0.0075^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.5169                                                  0.3341                                                  0.1339                                                    0.2408
  *USP45*         rs41288947    0.4383                                                  0.1373                                                  0.2641                                                    0.0162^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.6636                                                  0.1341                                                    0.0063^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0682
  *PHACTR1*       rs9369640     0.1667                                                  0.4673                                                  0.8831                                                    0.5247                                                0.8191                                                  0.7417                                                  0.6674                                                    0.4133
                  rs1333048     0.2947                                                    0.0251^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.5799                                                    0.0156^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.3204                                                  0.6650                                                  0.5825                                                    0.2450
                  rs838880      0.9565                                                    0.0108^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.3044                                                    0.0045^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.7818                                                  0.7699                                                  0.8126                                                    0.2552
  *STIM1*         rs116855870   0.1425                                                  0.2455                                                  0.6418                                                    0.8631                                                0.7116                                                  0.5285                                                  0.7357                                                    0.3365
                  rs2523644     0.4105                                                  0.2101                                                  0.6604                                                    0.0773                                                0.0627                                                    0.0449^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2968                                                    0.2580
  *MKI67*         rs145121731   0.0903                                                  0.2528                                                  0.2203                                                    0.0138^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.4030                                                    0.0048^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2459                                                    0.5059
  *FAM170B-AS1*   rs73302786    0.2662                                                  0.6366                                                  0.2511                                                    0.2687                                                0.8989                                                  0.8203                                                  0.2323                                                    0.5404
                  rs6067640       0.0380^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2144                                                  0.7990                                                    0.0077^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.6995                                                  0.1809                                                  0.6901                                                    0.9347
  *GFY*           rs73053944      0.0145^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.5731                                                  0.5880                                                    0.2471                                                0.8788                                                  0.6316                                                  0.4534                                                    0.9116
  *WDR37*         rs10794720    0.6272                                                    0.0103^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.9125                                                    0.6954                                                0.6528                                                  0.1352                                                  0.7804                                                    0.0458^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
  *SKIV2L*        rs592229        0.0014^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.0754                                                  0.0752                                                    0.0157^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.7557                                                  0.1230                                                  0.3617                                                    0.1727
                  rs6537384     0.3890                                                  0.1107                                                  0.2980                                                    0.3818                                                  0.0344^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.0808                                                  0.0620                                                    0.7745
                  rs10757283    0.8792                                                    0.0082^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.9667                                                    0.0420^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.4745                                                    0.0342^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.8876                                                    0.4636
  *CDKN2B-AS1*    rs1011970       0.0443^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.0628                                                  0.6524                                                    0.0834                                                0.5456                                                  0.4293                                                  0.6420                                                    0.3237
  *PRKG1*         rs9414827     0.6287                                                  0.8365                                                  0.6694                                                    0.0424^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.1488                                                  0.6060                                                    0.0291^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0549
                  rs197932      0.1918                                                    0.0272^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.5146                                                    0.5673                                                0.2395                                                  0.3102                                                  0.7843                                                    0.4625
  *LINC00354*     rs4907518     0.2933                                                  0.8434                                                  0.3915                                                    0.1285                                                  0.0028^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.6454                                                  0.6846                                                    0.7513
  *LIPE*          rs34052647    0.1525                                                  0.7148                                                  0.0040a                                                   0.4199                                                0.0801                                                  0.0879                                                  0.0940                                                    0.0081^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
  *BTRC*          rs2270439     0.3191                                                  0.9636                                                  0.1684                                                    0.1393                                                0.9515                                                  0.2852                                                  0.4689                                                    0.5780
  *TNS3*          rs11763932    0.4812                                                  0.6129                                                  0.9920                                                    0.8857                                                0.1424                                                  0.9598                                                  0.9307                                                    0.9591
  *TNS1*          rs918949      0.1509                                                  0.0510                                                  0.3218                                                    0.5993                                                0.7044                                                  0.5484                                                  0.6955                                                    0.9461
                  rs12229654      0.0203^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.3290                                                  0.1080                                                  \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0171^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.1167                                                  0.2297                                                  \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
                  rs4014195     0.1622                                                    0.0445^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0270^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.1811                                                0.7090                                                  0.3732                                                  0.5607                                                    0.2233
  *PANK1*         rs11185790    0.3638                                                  0.4169                                                  0.1750                                                    0.2583                                                0.3889                                                    0.0149^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.6355                                                    0.3282
                  rs507666      0.9872                                                    0.0084^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.7080                                                    0.0370^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0129^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.4210                                                  0.9126                                                    0.6992
  *MON2*          rs11174549      0.0283^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0133^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.8790                                                    0.3587                                                  0.0325^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2617                                                  0.6406                                                    0.9153
  *HECTD4*        rs2074356       0.0285^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.1092                                                    0.0109^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0002^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.0174                                                  0.1786                                                  \<0.0001^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^
  *CUBN*          rs78201384    0.1429                                                  0.9473                                                  0.7525                                                    0.0027^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0269^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0327^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.9812                                                    0.3888
  *PLUT*          rs954750      0.9214                                                    0.0212^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.6905                                                    0.8004                                                0.8585                                                    0.0264^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2382                                                    0.8865
  *ABCA1*         rs1883025     0.8085                                                  0.2006                                                    0.0134^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.3092                                                0.0667                                                  0.8891                                                  0.4019                                                    0.3377
                  rs10514995      0.0014^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^     0.0353^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^   0.2529                                                    0.3708                                                0.7542                                                  0.0855                                                  0.5232                                                    0.0365^[a](#tfn7-br-0-0-1152){ref-type="table-fn"}^

Data are P-values. The association between genotypes of each SNP and intermediate phenotypes was examined using Pearson\'s χ^2^ test. SNP, single nucleotide polymorphism; DM, diabetes mellitus; hyper-TG, hypertriglyceridemia; hypo-HDL, hypo-HDL-cholesterolemia; hyper-LDL, hyper-LDL-cholesterolemia; CKD, chronic kidney disease.

P\<0.05 was considered to indicate a statistically significant difference.

###### 

Association between genes, chromosomal loci and SNPs associated with coronary artery disease in the present study and previously examined cardiovascular disease-related phenotypes.

  Gene/chr. locus   SNP           Chr.   Position    Previously examined phenotypes
  ----------------- ------------- ------ ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1p13.3            rs602633      1      109278889   CAD (23202125, 20032323), LDL-cholesterol (20686565, 23063622, 19060906, 21943158, 18193043, 18262040, 19913121, 21977987, 20339536), HDL-cholesterol (23063622, 20686565), total cholesterol (20686565, 23063622)
  *SLC16A1*         rs1049434     1      112913924   HDL-cholesterol (23063622)
  *RNF2*            rs1046592     1      185100429   None
  *MIA3*            rs2936051     1      222629862   CAD (19198612, 21347282, 23364394, 21378990, 17554300, 22319020, 21966275), MI (19198609)
  2p13              rs13427905    2      71846585    None
  *CCDC141*         rs13419085    2      178837710   Heart rate (23583979, 20639392), left ventricular mass (19584346)
  *TNS1*            rs918949      2      217809974   Lung function, forced expiratory volume in
                                                     1 second (20010834, 21946350, 23284291)
  *YEATS2*          rs76174573    3      183804099   None
  4q24              rs6825911     4      110460482   Systolic BP (21572416), diastolic BP (21572416)
  4q31.2            rs6537384     4      145949613   None
  5q12              rs10514995    5      66443611    None
  *PHACTR1*         rs9369640     6      12901209    CAD (21378988, 23202125, 22745674, 21347282, 23364394, 21378990, 22751097, 22745674), MI (19198609, 21378990), ischemic stroke (22306652)
  *PSORS1C1*        rs3094663     6      31139310    Type 1 diabetes (17554300, 17632545), triglycerides (20686565), total cholesterol (20686565)
  *CCHCR1*          rs130071      6      31148433    Triglycerides (20686565)
  6p21.3            rs2523644     6      31374707    Type 1 diabetes (17554300, 17632545), LDL-cholesterol (23063622, 20686565), triglycerides (23063622, 20686565), total cholesterol (23063622, 20686565)
  *SKIV2L*          rs592229      6      31962664    CAD (21971053), type 1 diabetes (17554300, 17632545), LDL-cholesterol (20686565), triglycerides (20686565), total cholesterol (20686565)
  *USP45*           rs41288947    6      99446210    None
  *ITGB8*           rs80015015    7      20401881    None
  *TNS3*            rs11763932    7      47567880    None
  *CDKN2B-AS1*      rs1011970     9      22062135    CAD (21347282), LDL-cholesterol (23063622), abdominal aortic aneurysm (20622881), type 2 diabetes (17463249)
  9p21              rs1333048     9      22125348    CAD (23202125, 21606135, 19198612, 17634449, 20032323, 23364394), MI (17478679), intracranial aneurysm (22961961)
  9p21              rs10757283    9      22134173    Type 2 diabetes (20581827)
  *ABCA1*           rs1883025     9      104902020   HDL-cholesterol (20686565, 23505323, 23063622, 21909109, 19060911, 21347282, 19060906, 18193043, 18193044, 18193046, 22629316, 20864672, 21347282, 23726366), LDL-cholesterol (20686565), total cholesterol (20686565, 23063622, 20339536)
  9q34.2            rs507666      9      136149399   Venous thrombosis (22675575), VLDL-cholesterol
                                                     small lipoprotein fraction concentration (19936222), LDL-cholesterol lipoprotein fraction concentration (19936222)
  *WDR37*           rs10794720    10     1110225     Estimated glomerular filtration rate (20383146, 22479191), serum creatinine (20383146)
  *CUBN*            rs78201384    10     17111024    LDL-cholesterol (23063622), HDL-cholesterol (23063622), total cholesterol (23063622)
  FAM170B-AS1       rs73302786    10     49131709    None
  *PRKG1*           rs9414827     10     51137314    None
  *PANK1*           rs11185790    10     89612776    Insulin concentration (19060910)
  *BTRC*            rs2270439     10     101550817   None
  *MKI67*           rs145121731   10     128102595   None
  *STIM1*           rs116855870   11     4055527     None
  *OR52E4*          rs11823828    11     5884973     None
  11q13.1           rs4014195     11     65739351    Serum urate (23263486), serum creatinine (20383146), estimated glomerular filtration rate (20383146)
  *KIAA1551*        rs10771894    12     31982009    None
  *MON2*            rs11174549    12     62565357    None
  12q24.1           rs12229654    12     110976657   HDL-cholesterol (21909109)
  *ALDH2*           rs671         12     111803962   CAD (21971053, 21572416, 23202125), MI (21971053), LDL-cholesterol (21572416, 20686565), HDL-cholesterol
                                                     (21572416, 21372407), total cholesterol (20686565), systolic BP
                                                     \(21572416\), diastolic BP (21572416, 21909115), serum creatinine
                                                     \(22797727\), estimated glomerular filtration rate (22797727), type 1 diabetes (17554300)
  *HECTD4*          rs2074356     12     112207597   CAD (21971053, 21572416, 22751097, 19820697, 23364394, 23202125), MI (19820697), LDL-cholesterol (21572416, 20686565), HDL-cholesterol (21572416, 21909109, 22751097), total cholesterol
                                                     \(20686565\), systolic BP (21572416, 21909115), diastolic BP
                                                     (21572416, 21909115, 19862010, 19430479, 22751097), hypertension (21572416), serum creatinine (22797727), estimated
                                                     glomerular filtration rate (22797727), type 1 diabetes (18978792)
  12q24.31          rs838880      12     124777047   HDL-cholesterol (20686565)
  *PLUT*            rs954750      13     27889801    None
  13q34             rs7333181     13     111568950   None
  *LINC00354*       rs4907518     13     111898209   None
  *TRPM1*           rs2241493     15     31070149    None
  *PLCB2*           rs200787930   15     40289298    Triglycerides (23063622)
  *ADAT1*           rs145161932   16     75612670    None
  *KRT27*           rs17558532    17     40779624    None
  17q21.3           rs197932      17     46896981    Pulse pressure (21909110), systolic BP (21909110, 21909115)
  *GOSR2*           rs1052586     17     46941097    Pulse pressure (21909110), systolic BP (21909110, 21909115)
  *LIPE*            rs34052647    19     42407617    None
  *APOE*            rs7412        19     44908822    LDL-cholesterol (23100282, 23063622, 20686565, 22629316, 19060911, 23067351, 23696881, 20838585), HDL-cholesterol
                                                     \(21386085\), triglycerides (23063622, 20686565, 22629316, 19060911, 21386085), total cholesterol (23063622, 20686565)
  *GFY*             rs73053944    19     49427038    None
  20q13.2           rs6067640     20     51092837    None
  *EIF3L*           rs9466        22     37877742    None

Data were obtained from the GRASP Search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with a P-value of \<1.0×10^−6^. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphisms; Chr., chromosome; HDL, high density lipoprotein; LDL, low density lipoprotein; CAD, coronary artery disease; MI, myocardial infarction; BP, blood pressure.

###### 

Gene ontology analysis of the 21 genes identified in the present study.

  Gene          Function                                                                                                                                                                                                                            Biological process
  ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *RNF2*        Ubiquitin-protein transferase activity, chromatin binding, zinc ion binding, transferase activity, metal ion binding, ubiquitin protein ligase activity, RING-like zinc finger domain binding                                       Histone H2A-K119 monoubiquitination, negative regulation of transcription by RNA polymerase II, regulation of DNA-templated transcription, germ cell development, negative regulation of DNA binding transcription factor activity, negative regulation of G0 to G1 transition
  *YEATS2*      Modification-dependent protein binding, RNA polymerase II transcription factor activity, sequence-specific DNA binding                                                                                                              Negative regulation of transcription by RNA polymerase II, histone H3 acetylation, negative regulation of DNA-templated transcription
  *USP45*       Thiol-dependent ubiquitin-specific protease activity, cysteine-type peptidase activity, zinc ion binding, thiol-dependent ubiquitinyl hydrolase activity                                                                            Protein deubiquitination, ubiquitin-dependent protein catabolic process, DNA repair, global genome nucleotide-excision repair
  *ITGB8*       Extracellular matrix protein binding, signaling receptor binding                                                                                                                                                                    Ganglioside metabolic process, cell adhesion, integrin-mediated signaling pathway, regulation of gene expression, positive regulation of angiogenesis, cartilage development, extracellular matrix organization, cell-matrix adhesion
  *TNS3*        Protein binding, focal adhesion                                                                                                                                                                                                     Positive regulation of cell proliferation, cell migration, lung alveolus development
  *FAM170B*     Protein binding, outer acrosomal membrane                                                                                                                                                                                           Positive regulation of acrosome reaction, regulation of fertilization
  *PRKG1*       cGMP-dependent protein kinase activity, calcium channel regulator activity, nucleotide binding, ATP binding, transferase activity, cGMP binding, protein serine/threonine kinase activity, cGMP-dependent protein kinase activity   Negative regulation of vascular smooth muscle cell proliferation and migration, neuron migration, cGMP-mediated signaling, dendrite development, forebrain development, relaxation of vascular smooth muscle, regulation of GTPase activity, negative regulation of platelet aggregation, actin cytoskeleton organization
  *BTRC*        Ubiquitin-protein transferase activity, ubiquitin protein ligase activity, β-catenin binding, protein phosphorylated amino acid binding, protein dimerization activity                                                              Protein polyubiquitination, ubiquitin-dependent protein catabolic process, regulation of circadian rhythm, regulation of canonical Wnt signaling pathway, protein dephosphorylation, mammary gland epithelial cell proliferation, regulation of I-κB kinase/NF-κB signaling, positive regulation of DNA-templated transcription, G2/M transition of mitotic cell cycle, negative regulation of DNA binding transcription factor activity, stress-activated MAPK cascade, interleukin-1-mediated signaling pathway
  *MKI67*       RNA binding, DNA binding, ATP binding, protein binding                                                                                                                                                                              Regulation of mitotic nuclear division, regulation of chromosome segregation and organization, cell proliferation
  *STIM1*       Calcium channel regulator activity, calcium ion binding, microtubule plus-end binding, metal ion binding, protein binding                                                                                                           Cellular calcium ion homeostasis, activation of store-operated calcium channel activity, regulation of calcium ion transport, positive regulation of angiogenesis, regulation of cardiac conduction
  *OR52E4*      Olfactory receptor activity, G-protein coupled receptor activity                                                                                                                                                                    Signal transduction, G-protein coupled receptor signaling pathway, detection of chemical stimulus involved in sensory perception of smell
  *KIAA1551*    Uncharacterized                                                                                                                                                                                                                     
  *MON2*        Protein binding, protein transport                                                                                                                                                                                                  Golgi to endosome transport
  *PLUT*        Uncharacterized                                                                                                                                                                                                                     
  *LINC00354*   Uncharacterized                                                                                                                                                                                                                     
  *TRPM1*       Ion channel activity                                                                                                                                                                                                                G-protein coupled glutamate receptor signaling pathway, ion transmembrane transport, protein tetramerization, cellular response to light stimulus
  *ADAT1*       RNA binding, tRNA-specific adenosine deaminase activity, hydrolase activity, metal ion binding                                                                                                                                      tRNA processing
  *KRT27*       Structural molecule activity, intermediate filament                                                                                                                                                                                 Hair follicle morphogenesis, keratinization, cornification
  *LIPE*        Triglyceride lipase activity, serine hydrolase activity, protein kinase binding, hormone-sensitive lipase activity                                                                                                                  Protein phosphorylation, lipid metabolic process, steroid metabolic process, cholesterol metabolic process, triglyceride catabolic process, long-chain fatty acid catabolic process, diacylglycerol catabolic process
  *GFY*         Protein localization to non-motile cilium, non-motile cilium assembly                                                                                                                                                               Sensory perception of smell, response to stimulus
  *EIF3L*       Translation initiation factor activity, RNA binding, protein binding                                                                                                                                                                Translational initiation, viral translational termination-reinitiation

Data for predicted functions and biological processes of the genes were obtained from database of Gene Ontology and GO Annotations (QuickGO; <http://www.ebi.ac.uk/QuickGO/>).
